Vir Biotechnology, Inc.
Every calculator, already run for VIR
Open the full toolkit →You have the numbers on VIR. Get the argument.
A written report on which of these readings actually decide the outcome for Vir Biotechnology, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
9 analysts covering VIRAnalyst Price Target Disagreement for Vir Biotechnology, Inc.
Wall Street's bull case implies +120% from the current price; the bear case implies +25%. A 95% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for VIR
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amende…
VIR — frequently asked
Is VIR a buy right now?
Wall Street's consensus rating on Vir Biotechnology, Inc. is Strong Buy across 9 analysts, with a mean price target of $21.50 (+58% vs. the current $13.65). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
What is the analyst price target disagreement for Vir Biotechnology, Inc.?
Analysts covering Vir Biotechnology, Inc. (VIR) range from a bear-case target of $17.00 to a bull-case high of $30.00, with a mean consensus target of $21.50 across 8 analysts. The spread of $13.00 (95% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Vir Biotechnology, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Vir Biotechnology, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full VIR research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Vir Biotechnology, Inc., in minutes. 3 free reports included with every account — no credit card required.